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In the mouse model, the arbovirus Venezuelan equine encephalitis virus (VEE) replicates in lymphoid tissues prior to
either inducing protective immunity (attenuated VEE mutant) or progressing to lethal encephalitis (virulent parent VEE). To
investigate the mechanism of the protective response, cytokine gene expression was examined during the course of the
primary in vivo immune response to molecularly cloned, virulent VEE and a single-site attenuated VEE mutant, using a
quantitative reverse transcriptase-polymerase chain reaction assay. VEE-induced cytokine gene expression was 100-fold
elevated over that of untreated controls for IFN-g and IL-6 and 10-fold increased for IL-12, IL-10, and TNF-a. There was
no qualitative difference in cytokine gene induction comparing mice infected with the attenuated and the virulent VEE;
however, there were significant differences in the cytokine gene expression kinetics. In mice infected with the attenuated
VEE, elevated cytokine gene expression was delayed 24 hr when compared to mice infected with the virulent parent VEE
clone at the same dose. Further, IFN-g protein secretion by cells from the draining lymph node mimicked the pattern of
IFN-g gene induction by cells harvested from the same site. IFN-g gene expression was elevated at an earlier time point
in mice given virulent V3000 24 hr after attenuated V3032 injection compared to mice infected with virulent V3000 alone.
The combined V3000/V3032 infection resulted in host protection. Treatment of mice with IL-12 prior to infection with virulent
VEE failed to reduce the severity of infection, while anti-IL-12 antibody did not prevent the early protective effect of attenuated
virus. In contrast, administration of anti-IFN-a/b antibody prior to VEE infection worsened virulent VEE disease. These
results indicate that the attenuated VEE strain elicits a similar but delayed cytokine response compared to the virulent strain,
suggesting that the kinetics of cytokine expression and the particular cytokine produced may influence the development of
a host protective response. Furthermore, IFN-a/b, but not IL-12, seems to be a major factor in the induction of early
protection against VEE infection and disease. q 1997 Academic Press
INTRODUCTION protective immune response to the attenuated VEE has
not been compared to the response elicited by the viru-
Venezuelan equine encephalitis virus (VEE), an
lent VEE.
alphavirus in the family Togaviridae, is one of the etiologi-
The importance of the antiviral activity of interferons [in-
cal agents of mosquito-borne encephalitis in the Ameri- terferon-a/b (IFN-a/b) and interferon-g (IFN-g)] in the early
cas (Calisher, 1994). VEE offers a useful model for the phase of viral infections has been well established (re-
study of various aspects of acute viral encephalitis at the viewed in Gresser, 1984). However, different viruses and
molecular level, because of the availability of molecularly virus isolates display varying susceptibility to the inhibiting
cloned viruses and a well-characterized mouse model. effects of IFNs (Moskophidis, 1994). The potent IFN-g-in-
In earlier studies, we demonstrated that administration ducing activity of IL-12 has more recently been shown to
of molecularly cloned, single-site attenuated mutant VEE contribute to the broad antiviral activity previously associ-
could induce protection against challenge with molecu- ated with IFN-g. IL-12 activities include augmentation of
larly cloned virulent VEE given 24 to 36 hr prior to virulent cytotoxic T cell activity, enhanced proliferation of activated
VEE infection (Grieder et al., 1996). This rapid response T and NK cells, inhibition of IgE production, and induction
may involve both innate and adaptive components of the of T helper 1 (Th1) cytokine profiles (Orange, 1994). There-
immune response, which cooperate to mediate a rapid fore, both IFN-g and IL-12, as well as other cytokines asso-
arrest of the infectious process. The immune response ciated with the type 1 immune response, have been the
against the attenuated and virulent VEE strains may po- focus of a number of studies involving viral pathogenesis
tentially differ in terms of the particular cytokines induced (Farrar and Schreiber, 1993; Wesseligh et al., 1994; Whar-
and by their level of expression. As yet, however, the tenby et al., 1995).
In this investigation, we have examined the kinetics of
type 1 (IFN-g, IL-2, and IL-12) and type 2 (IL-4, IL-6, and1 To whom reprint requests should be addressed. Fax: (301) 295-
1545. E-mail: grieder@usuhsb.usuhs.mil. IL-10) cytokine gene expression in different lymphoid tis-
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sues during the course of the early immune response macrophages were distinct from virulent V3000 growth
kinetics in that attenuated V3032 was characterized byagainst virulent or attenuated VEE. We hypothesized that
type 1 cytokine expression may be favored in the immune a 18-hr lag phase and slower growth that resulted in
higher peak titers (Grieder and Nguyen, 1996). Addition-response to the attenuated VEE compared to the virulent
strain. We further evaluated through in vivo intervention ally, specific macrophage activation inhibited or com-
pletely negated replication of attenuated V3032 whereasexperiments the relative importance of IL-12 and IFN-a/
b in the development of the protective response. Our virulent V3000 growth was affected only minimally
(Grieder and Nguyen, 1996). Attenuated virus dissemina-results demonstrated that there is a consistent and tightly
regulated cytokine gene expression pattern that is asso- tion in the mouse following footpad injection resembled
virulent V3000 dissemination except that limited virusciated with rapid increases in IFN-g, IL-6, IL-10, IL-12,
and TNF-a in the absence of elevations in either IL-2 or was detected in the serum and no virus could be isolated
from the brain, presumably contributing to the V3032’sIL-4 during responses to both attenuated and virulent
VEE. Although the cytokines produced were similar in attenuated phenotype (Grieder et al., 1995). Additionally,
in the attenuated V3032 virus, the attenuating E2-209the two VEE strains, there was a consistent delay in the
onset of the response against the attenuated virus, which position appeared to revert back to the virulent genotype
only on rare occasions (Johnston and Grieder, unpub-correlated with the delay in attenuated virus dissemina-
tion. Administration of attenuated V3032 24 hr prior to lished observation).
virulent V3000 infection induced host protection and was
Antibody and cytokineassociated with a more rapid elevation in IFN-g gene
expression. Furthermore, administration of anti-IFN-a/b
Anti-IFN-a/b antibody was provided by Dr. Ion Gresser
antibody decreased the average survival times of mice
(Viral Oncology, Villejuif Cedex, France). This sheep anti-
infected with virulent VEE without apparent effect on the
IFN-a/b antibody had a neutralization titer of 1:106 against
attenuated mutant VEE. IL-12 supplementation had no
8 units of IFN-a/b and was intravenously injected as 200-
effect on the overall mortality rate of virulent VEE, being
ml volumes per animal at 4 and 48 hr prior to infection with
unable to ameliorate the severe and fatal disease. And
VEE. The anti-IL-12 antibody has previously been described
finally, anti-IL-12 antibody administered prior to inocula-
(Williamson et al., 1996) and was injected intravenously at
tion with attenuated VEE did not alter the protective effect
a concentration of 0.5 mg in a volume of 200 ml of saline
of attenuated virus against virulent VEE. Therefore, pro-
24 hr before infection with VEE. Control mice were injected
tective immune responses against fatal encephalitis ap-
with control goat serum at the same concentration. IL-12
pears to be influenced by IFN-a/b, but not IL-12.
was prepared as previously described (Sedegah et al.,
1994) and stored at 0907. Thirty nanograms of IL-12 in 200
MATERIALS AND METHODS ml saline was injected ip 72, 48, 24, and 0 hr before infection
with VEE, a dose previously shown to be protective againstAnimals
Cryptosporidium and Plasmodium (Sedegah et al., 1994;
Six- to eight-week-old, female C57BL/6 mice were ob- Urban et al., 1996).
tained from the National Cancer Institute (Bethesda, MD)
and maintained in the AALAC accredited animal facility Reverse transcriptase-polymerase chain reaction (RT-
at the Uniformed Services University of the Health Sci- PCR) for the analysis of cytokine gene induction
ences. This strain is well characterized for VEE patho- following VEE infection
genesis and has been used extensively in our laboratory.
The quantitative, coupled RT-PCR was performed asExperimental groups contained five mice for cytokine
previously described (Svetic et al., 1991). Briefly, follow-analysis and six or nine mice for mortality protection and
ing RNA isolation, purification, and quantification, reverseaverage survival time determination.
transcription of RNA was carried out at 377 for 60 min
followed by a 5-min incubation at 907 and chilling to 07.Virus
Complementary DNA (cDNA) amplification was estab-
lished using previously described primers (Svetic et al.,Two molecularly cloned VEE strains (virulent V3000
and attenuated V3032) were used in all the experiments 1991) under optimal cycle numbers at which input mRNA
varied linearly with the final product. In addition, induc-described in this report (Davis et al., 1989, 1990). V3032
differs from virulent parent V3000 by the replacement of ible IL-12 (p40) mRNA was measured using sense (5*-
ACC AGC TTC TTC ATC AGG-3*) and antisense primersglutamic acid for a lysine in the E2 glycoprotein position
209. The growth properties of the single-site VEE mutant (5*-CTT TGC ATT GGA CTT CGG-3*) and a probe (5*-
AGT ACC CTG ACT CCT GGA-3*) that were developedV3032 in BHK cells were similar to those of virulent V3000
with the exception that attenuated V3032 grew to higher and successfully used in previous experiments to detect
elevation in IL-12 message. To verify that equal amountstiters. In contrast, attenuated V3032 growth kinetics in
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of undegraded RNA were added in each RT-PCR within RESULTS
an experiment, the ‘‘housekeeping gene’’ hypoxanthine-
VEE infection induces elevated cytokine gene
guanine phosphoribosyl transferase (HPRT) was used
expression
as an endogenous internal standard and amplified with
specific primers at the number of cycles at which a linear Attenuated VEE can elicit a protective immune response
to virulent VEE if administered 24 hr prior to infection withrelationship between input RNA and final HPRT product
was detected (Gause and Adamovicz, 1994). Amplified the virulent VEE. To compare the in vivo immune response
to these two viral strains, mice were infected in the left rearproducts were detected by standard Southern blot analy-
sis, and the resultant signal was quantitated with a Phos- footpad, and 1, 6, 24, 48, and 72 hr later the left popliteal
lymph node, the contra lateral lymph node, and the spleenphorImager (Molecular Dynamics, Sunnyvale, CA), which
uses a phosphor screen instead of film to detect radioac- were removed and prepared for analysis of cytokine gene
expression by RT-PCR. Cytokines associated with both typetive signals on the Southern blot (Sevtic et al., 1991).
1 and type 2 immune responses were included: IL-2, IL-4,
Cytokine assays—ELISPOT IL-6, IL-10, IL-12(p40), IFN-g, and TNF-a (Figs. 1–3; Table
4). IFN-g and IL-6 steady state mRNA levels in the draining
The frequency of IFN-g-producing cells was deter-
(left) popliteal lymph nodes were 100-fold elevated in in-
mined by an ELISPOT assay as previously described
fected compared to uninfected mice within 24 hr after infec-
(Morris et al., 1994). Briefly, wells were coated with 10
tion with either virulent V3000 or attenuated V3032 (Figs.
mg/ml of the capture anti-IFN-g antibody (R46A2) and
1a and 1b). However, the time course of elevated cytokine
bound IFN-g was detected with 4 mg/ml of biotinylated
gene induction was markedly different for the two viruses:
anti-IFN-g antibody (XMG6) (Neta et al., 1994).
following virulent V3000 infection, the 100-fold increases of
IFN-g and IL-6 were measured at 6 hr postinfection (p.i.),Mortality experiments
while similar IFN-g and IL-6 increases were not observed
until 24 hr p.i. with attenuated V3032. Eight to 10-fold in-Groups of nine C57BL/6 mice were intravenously in-
jected with 0.5 mg anti-IL-12 antibody at 24 hr and/or creases in gene expression following infection with V3000
or V3032 were observed for IL-12(p40), IL-10, and TNF-aanti-IFN-a/b antibody at 48 and 4 hr before infection
with VEE. The control group was administered an equal (Figs. 1c–1e) in the draining lymph node. Again, peak cyto-
kine mRNA levels were reached at 6 hr p.i. following virulentamount of normal sheep immunoglobulin at the appro-
priate time points. Virus injections were administered at V3000 infection, while mice infected with attenuated V3032
peak levels were delayed until 24 hr p.i. IL-2 and IL-4 gene103 plaque-forming units (PFU) into the left (attenuated
V3032) or right (virulent V3000) rear footpad using molec- expressions were less than 3-fold increased over those of
untreated controls following infection with either virulent orularly cloned virulent or attenuated VEE. Mice were ob-
served for a period of 14 days when percentage mortality attenuated VEE (Figs. 1f–1g). These results indicate that
both virulent VEE and attenuated VEE induce similar cyto-and average survival times were calculated. Two-sided
Student’s T tests were used for statistical analysis. kine gene expression patterns including elevation of both
Th1 and Th2 cytokines; however, cytokine elevations areTwenty-four hours before infection with VEE, groups
of eight C57BL/6 mice were administered anti-IL-12 anti- delayed in mice infected with attenuated V3032 compared
to virulent V3000. The different mRNA cytokine kinetics par-body at a dose shown previously to inhibit IL-12 activity
in vivo (Williamson et al., 1996). Control mice were in- allels the delayed appearance of attenuated V3032 follow-
ing spread from the footpad inoculation site when com-jected with control antibody at the same concentration
as the anti-IL-12 antibody. Mice administered anti-IL-12 pared to virulent V3000 (Grieder et al., 1995).
As demonstrated previously (Grieder et al., 1995), afteror control antibody were inoculated into their left rear
footpad with 103 PFU of attenuated V3032 followed 24 hr footpad injection and rapid, initial spread of VEE to the
draining lymph node, both attenuated V3032 and virulentlater with 102 PFU of virulent V3000 into their right foot-
pad. Control mice were injected with either attenuated V3000 disseminate to other lymphoid tissues (e.g.,
spleen, peripheral lymph nodes). To evaluate the patternV3032 or virulent V3000 alone (data not shown). Percent-
age mortality and average survival times were calculated of increased cytokine gene expression in different tis-
sues distal to the site of infection, the spleen and rightfor each group for an observation period of 14 days.
Groups of six C57BL/6 mice were ip injected with 30 (nondraining) popliteal lymph node were also analyzed
at 0, 6, 24, 48, 72, and 96 hr after injection into the leftng IL-12 per mouse at 72, 48, 24, and 0 hr prior to infection
with VEE. Molecularly cloned virulent virus was injected footpad. Thus, the kinetics of cytokine gene elevations
could be compared both within and between lymphoidinto the left rear footpad at a dose range of 100, 101,
102, and 103 PFU per injection. Percentage mortality and organs. In the nondraining popliteal lymph node (Fig.
2), IFN-g and IL-6 mRNA levels again showed markedaverage survival times were calculated and statistical
analysis was performed as described. increases which peaked at 24 hr (virulent V3000) and 48
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FIG. 1. Virulent and attenuated VEE induce elevations in IFN-g, IL-6, IL-10, IL-12, and TNF-a cytokine gene expression in the draining lymph
nodes of mice infected with VEE. Mice were inoculated with 103 PFU of virulent V3000 or attenuated V3032 into their rear left footpad and draining
popliteal lymph nodes were harvested for in vivo cytokine gene induction measured by quantitative RT-PCR. Specific primers were used for IFN-g
(a), IL-6 (b), IL-12 (c), IL-10 (d), TNF-a (e), IL-2 (f), and IL-4 (g). The mean and standard error (SE) derived from cells harvested from the draining
popliteal lymph nodes of five individual C57BL/6 mice are shown for each time point and treatment. All data were individually normalized to the
housekeeping gene HPRT, which did not show changes greater than twofold to threefold throughout the experiment. The means are expressed
relative to the mean of the untreated control, which was arbitrarily given a value of 1. The data were quantitated using a PhosphorImager. Similar
results were obtained in other independent experiments.
hr (attenuated V3032), but at levels 3- to 5-fold lower than virulent V3000 and attenuated V3032 infection. This is
not unexpected, because both viruses reach the spleencorresponding mRNA levels in the draining lymph node.
Additionally, the only other increased cytokine was IL-12 at the same time, i.e., 12 hr p.i. Taken together, these
findings indicate that the cytokines induced with protec-following virulent V3000 infection, while attenuated
V3032 infection did not result in significantly increased tive, attenuated, and virulent strains of VEE do not differ
qualitatively, but instead differ in their cytokine inductioninduction of any other cytokine measured. In the spleen
(Fig. 3), greater than 10-fold increased levels in IFN-g, kinetics with the protective strain exhibiting a signifi-
cantly delayed response.IL-6, and IL-10, and 3- to 5-fold increases in IL-12 and
TNF-a were measured following V3000 infection, while
attenuated V3032 infection stimulated lesser increases Both virulent and attenuated VEE induce IFN-g-
in IFN-g, IL-6, IL-10, and IL-12 expression in this organ. secreting cells in the draining popliteal lymph node
Kinetics of spleen cytokine mRNA elevations were similar
to those in other tissues with the exception that there was In order to evaluate the actual cytokine protein se-
cretion following VEE infection, the number of IFN-g-no significant difference in cytokine induction between
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FIG. 2. Virulent and attenuated VEE induce elevations in IFN-g, IL-6, and IL-12 cytokine gene expression in the nondraining lymph nodes of mice
infected with VEE. Cytokine gene expression by cells in these tissues was analyzed as described in the legend to Fig. 1.
secreting cells in the draining popliteal lymph node IL-12 has no significant effect on the early immune
response against VEE(DPL) was enumerated in ELISPOT assays (Fig. 4) and
found to be significantly increased following VEE in-
The elevated levels of IL-12 gene expression in micefection when compared to uninfected mice. The kinet-
infected with VEE suggested a potential role for IL-12 inics of IFN-g-secreting cells closely followed eleva-
the early immune response as a stimulator of type 1 cellstions in IFN-g gene expression with an approximately
and natural killer cells to produce IFN-g. This hypothesis6- to 12-hr lag time between increased mRNA and
was tested in two in vivo experiments in which miceprotein. At 12 hr p.i. with virulent V3000, IFN-g-secre-
were either depleted of, or supplemented with, IL-12.ting cells were markedly increased at 100 cells/5 1
First, anti-IL-12 antibody given at a previously effective105 cells from the DPL. Elevated levels were observed
dose in vivo (Tripp et al., 1994; Williamson et al., 1996)for at least 36 hr p.i. In contrast, following attenuated
had no effect on the percentage of mortality and theV3032 infection elevations in the number of IFN-g-
average survival time of adult mice infected with VEE atsecreting cells were not observed until 24 hr p.i. and
a dose of 103 PFU of virulent V3000 or attenuated V3032these increases were more transient. These findings
(Table 1). In contrast, mice treated with anti-IFN-a/b anti-indicate a close association between elevations in
body prior to infection with 103 PFU of virulent V3000 hadIFN-g gene expression and protein secretion, and they
significantly reduced average survival times (8.0 { 0.7further confirm a delayed elevation in IFN-g following
days in control animals compared to 2.8 { 0.5 days ininfection with the attenuated compared to the virulent
VEE virus. anti-IFN-a/b antibody; Table 1). These findings indicate
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FIG. 3. Virulent and attenuated VEE induce elevations in IFN-g, IL-6, IL-10, and IL-12 cytokine gene expression in the spleens of mice infected
with VEE. Cytokine gene expression by cells in these tissues was analyzed as described in the legend to Fig. 1.
that blocking IFN-a, but not IL-12, can influence the pro- 103 to 100 PFU did not influence the mortality and average
survival times when compared to those mice injectedcess of VEE infection. Furthermore, to address whether
IL-12 mediated the attenuated V3032-induced protective with diluent prior to infection with the same dose of
V3000 (Table 3). These results confirmed the observationresponse to virulent V3000, anti-IL-12 antibody was ad-
ministered 24 hr prior to attenuated V3032 injection. The that IL-12 does not seem to affect the early immune re-
sponse against VEE. Moreover, this lack of altered im-IL-12 blocking treatment was used as described above.
Twenty-four hours after V3032 injection, mice were chal- mune response against V3000 following IL-12 supple-
mentation was demonstrated to be dose-independent;lenged with a lethal dose of virulent virus (Table 2). Our
results indicate that the protective effect conferred by i.e., IL-12 supplementation did not alter mortality or aver-
age survival time when mice were challenged with 1 PFUthe injection of 103 PFU attenuated V3032 24 hr prior to
challenge with 102 PFU virulent V3000 was not blocked of V3000.
by anti-IL-12 antibody treatment in vivo. Therefore, IL-12
activity is not exclusively responsible for the observed Attenuated V3032-induced protection changes the
early protective effect of attenuated V3032. cytokine profile following virulent V3000 challenge
The second experiment involved the direct administra-
tion of IL-12 prior to VEE infection. In vivo supplementa- The cytokine profiles in mice primed with the attenu-
ated V3032 24 hr prior to challenge with a lethal dose oftion of IL-12 at doses previously shown to be effective
with other pathogens (Williamson et al., 1996) prior to virulent V3000 was evaluated in both popliteal lymph
nodes and the spleen. Adult, female C57BL/6 mice wereinfection with virulent V3000 at virus doses ranging from
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V3000 followed by attenuated V3032 infection. This IFN-
g response was also of significantly shorter duration
compared to IFN-g gene expression levels following viru-
lent V3000 administration alone (Table 4).
DISCUSSION
The results of our experiments demonstrate that highly
virulent VEE elicits a consistent and restricted cytokine
gene expression pattern with elevations of both Th1 and
Th2 cytokines. A molecularly cloned mutant of VEE,
V3032, which has a single base pair change and elicits
a protective response, induces a cytokine pattern in mice
that is similar in both intensity and specificity, but differs
in the kinetics of upregulation as evidenced by a 24-hr
FIG. 4. Number of IFN-g-producing cells per 500,000 lymphocytes in
delay when compared to the virulent parent, V3000. Priorthe draining popliteal lymph node following VEE inoculation of C57BL/6
immunization with attenuated V3032 triggers a host pro-mice. Groups of five mice were inoculated with 103 PFU of virulent
V3000 or attenuated V3032 into their rear left footpad, and draining tective response following challenge with virulent V3000
popliteal lymph node was harvested to enumerate IFN-g-producing which is associated with a more rapid induction of IFN-
cells by ELISPOT assay. g gene expression compared to primary infection with
virulent V3000. In vivo blocking of IFN-a/b markedly ac-
celerates disease susceptibility following infection withinfected with 103 PFU of attenuated V3032 injected into
their left rear footpad. Twenty-four hours later, mice were virulent VEE, suggesting that in VEE infection IFN-a/b
plays a major role in host protection. In contrast, ourchallenged with 102 PFU of virulent V3000 into their right
footpad. Under these conditions, the right popliteal lymph findings suggest that IL-12 does not play a major role in
the host protective response.node becomes the draining lymph node for the final viru-
lent VEE challenge. The induction of comparable levels of all the cytokines
tested in response to both the attenuated V3032 andSimilarly to results obtained following infection with
either virulent V3000 or attenuated V3032 alone, IFN-g the virulent V3000 suggests that viral structures, which
stimulate a rapid and highly specific cytokine responseand IL-6 mRNAs were elevated over 100-fold in the drain-
ing popliteal lymph node. Patterns of all the other cyto- in the host, are conserved in the two strains. The differ-
ence in the virion structures of attenuated V3032 com-kines tested (IL-6, IL-12, IL-10, TNF-a, IL-2, and IL-4) were
also comparable to those results previously described pared to virulent V3000 is limited to one nucleotide in
the viral gene encoding the E2 envelope protein. Bothfollowing single virus injections (data not shown). How-
ever, an accelerated IFN-g response characterized by alphavirus envelope proteins, E1 and E2, are glycosyl-
ated and membrane-anchored at their C-terminal endssignificantly higher IFN-g mRNA levels at 6 hr was ob-
served in the draining lymph node of mice given virulent (Rice et al., 1982). E1 and E2 form a stable heterodimer;
TABLE 1
Virulence of Molecularly Cloned VEE in Mice Following Administration of Anti-IL-12 and/or Anti-IFN-a/b Antibody
Anti-cytokine antibody treatment
Mortality and Anti-IL-12 and
average survival Control Anti-IL-12 Anti-IFN-a/b anti-IFN-a/b
Virus time Ab Ab Ab Ab
V3000 % Mort 100 100 100 100
AST { SE 8.0 { 0.7 7.6 { 0.5 2.8 { 0.5 2.7 { 1.5
V3032 % Mort 0 0 0 0
AST { SE — — — —
Note. Nine adult, female C57BL/6 mice were injected intravenously with 0.5 mg of anti-IL-12 antibody 24 hr before VEE infection and/or with 0.2
ml of sheep anti-IFN-a/b antibody (neutralization titer of 1:106 against 8 units of IFN-a/b) 48 and 4 hr prior to infection with 103 PFU of the indicated
virus derived from molecular clones. Percentage mortality and average survival time (AST) for those animals that died were calculated in days {
standard error ({SE) using an observation period of 14 days. All surviving mice were challenged ip with 104 PFU of V3000 at 3 weeks p.i. and
showed no clinical signs of disease.
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TABLE 2 tance of the host to attenuated V3032 was not a result
of qualitative shifts in the immune system as have beenAnti-IL-12 Antibody Treatment Effect on Early Protection
observed in other systems where the host has differedby Attenuated V3032
genetically (Sher and Coffman, 1992) or components of the
Anti-Cytokine treatment immune system have been manipulated (Finkelman et al.,
followed by attenuated V3032 1994). Rather, the major difference between attenuated
injection 24 hr prior to virulent
V3032 and virulent V3000 appears to be linked to the kinet-V3000 challenge
ics of the cytokine pattern, with the elevations detected in
Anti-IL-12 Ab / V3032 / V3000 11 % Mort cytokine gene expression being delayed by as much as
8.0 { 0 AST { SE 24 hr in the immune response to attenuated V3032. This
Control Ab / V3032 / V3000 11 % Mort delay corresponds to the delayed in vivo replication and
8.0 { 0 AST { SE
dissemination of attenuated V3032 compared to virulentPBS / V3032 / V3000 0 % Mort
V3000 (Grieder et al., 1995). Specifically, following rear foot-— AST { SE
pad inoculation of 103 PFU of virulent V3000, virus can be
Note. Nine adult, female C57BL/6 mice were injected intravenously isolated from the draining popliteal lymph node as soon
with 0.5 mg of anti-IL-12 antibody 24 hr before inoculation with 103 PFU as 4 hr p.i. In contrast, attenuated V3032 is undetectableof attenuated V3032 followed by challenge with 102 PFU of virulent
in the draining lymph node at this time point. However, ifV3000. Percentage mortality and average survival time (AST) for those
virulent V3000 is administered only 24 hr after inoculationanimals that died were calculated in days{ standard error ({SE) using
an observation period of 14 days. All surviving mice were challenged of attenuated V3032, a protective response against 100
ip with 104 PFU of V3000 at 3 weeks p.i. and showed no clinical signs lethal doses of the virulent virus is induced. It is possible
of disease.
that the delayed dissemination observed with attenuated
V3032 provides the host with sufficient time to develop a
protective immune response against the attenuated VEEthree of these E1-E2 dimers form trimer-dimer spikes
which is effective against subsequent challenge with viru-(Rice and Strauss, 1982). These alphavirus spike proteins
lent V3000. Our findings suggest that a similar responsefunction in receptor binding and it has been shown that
may be initiated against the virulent VEE, but that the rapidrelatively minor changes in E1 and E2 can alter viral
dissemination of the virus may overwhelm the host beforereceptor-specificity (Lustig et al., 1988; Tucker and Griffin,
this response can sufficiently develop to provide protec-1991) and host range (Burness et al., 1988). Furthermore,
tion. The protective immune response that occurs in re-specific sites on the alphavirus E2 glycoprotein, and to
sponse to virulent V3000 when attenuated V3032 is givena lesser degree on the E1 glycoprotein, have been char-
24 hr prior to V3000 infection suggested the possibility thatacterized by neutralizing monoclonal antibodies (Roeh-
the cytokine pattern may also be altered when comparedrig, 1986). For VEE, several antigenic sites were localized
to administration of V3000 alone. Indeed, we observedon the two envelope glycoproteins and found to be re-
significantly accelerated elevation in IFN-g mRNA levelssponsible for the induction of a protective immune re-
in mice given virulent V3000 24 hr after attenuated V3032sponse (Hunt and Roehrig, 1995; Agapov et al., 1994).
immunization. It will be important in future studies to exam-Additionally, amino acid residues in E2 positions 182
ine whether this early IFN-g response mediates the protec-and 207 were identified as targets for virus neutralization
tion conferred by attenuated V3032 or if additional cyto-(Roehrig and Mathews, 1995; Johnson et al., 1990).
In terms of the cytokine response, the increased resis- kines are involved.
TABLE 3
IL-12 Treatment Effect on Virulent V3000
Virulent V3000 injection into the rear footpad of 6 adult mice [PFU]
100 101 102 103
IL-12 82 100 100 100 % Mort
8.6 { 0.6 8.7 { 0.3 8.7 { 0.3 7.7 { 0.8 AST { SE
PBS 100 100 100 100 % Mort
9.0 { 0.3 8.2 { 0.7 9.2 { 0.4 7.3 { 0.6 AST { SE
Note. Six adult, female C57BL/6 mice were injected intraperitoneally with 30 mg of IL-12 at 72, 48, 24, and 0 hr before infection with virulent
V3000 at doses ranging from 103 to 100 PFU. Groups of control animals were inoculated with the same volume and frequency of diluent. Percentage
mortality and average survival time (AST) for those animals that died were calculated in days { standard error ({SE) using an observation period
of 14 days. All surviving mice were challenged ip with 104 PFU of V3000 at 3 weeks p.i. and showed no clinical signs of disease.
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TABLE 4 as IFN-g, following acute infection with either attenuated
or virulent VEE, similar to previous observations withIFN-g Gene Induction in Mice Infected with Molecularly Cloned
other viral pathogens (Coutelier et al., 1995; Schijns etVirulent VEE 24 hr after Injection with Attenuated VEE
al., 1995). However, supplementation of IL-12 in adult
Infection with molecularly cloned VEE mice prior to infection with very low doses of virulent
VEE did not alter the outcome of disease. Furthermore,
Attenuated V3032
blocking IL-12 with anti-IL-12 antibody at doses that havefollowed 24 hrs later
previously been shown to be effective at inhibiting IL-12Hr Virulent V3000 by virulent V3000
postinfection (mean { SE) (mean { SE) activity in vivo (Tripp et al., 1994) neither increased the
virulence of V3000 nor blocked the protective effect of
6 48 { 12 115* { 32 attenuated V3032.24 363 { 42 52* { 9
Previous studies have shown that administration of72 81 { 7 9* { 1
low doses of IL-12 (9 or 90 ng) during and after viral
Note. Groups of adult, female C57BL/6 mice were infected either infection suppressed LCMV infection, while high doses
with 102 PFU of virulent V3000 into the rear right footpad or with 103 of IL-12 (9 1 103 ng) caused increased viral replication
PFU of attenuated V3032 into the rear left footpad followed 24 hr later
(Orange et al., 1994, 1995a, 1995b). In the present study,by 102 PFU into the right footpad. The draining (right) popliteal lymph
we employed a low-dose IL-12 supplementation strategynodes were harvested for in vivo cytokine gene expression measure-
ments by quantitative RT-PCR. The mean and standard error ({SE) that has previously been shown to protect mice against
derived from cells harvested from four individual mice are shown at microbial infection (Sedegah et al., 1994). Adult mice
each time point. Data are expressed as the ratio of treated/untreated
were injected with a total of 120 ng of IL-12 distributedanimals.
into four identical doses, all administered prior to infec-* P  0.01, where virulent V3000 alone is compared to attenuated
V3032 followed by V3000 at 6, 24, and 72 hr postinfection (Student’s T tion with varying amounts of virulent V3000. The rationale
test). for using this strategy was that protection against 100
lethal doses, i.e., 100 PFU of virulent V3000 (1 PFU kills
an adult mouse, see Table 3), can be induced within 24
Resistance and susceptibility to a virus infection de- hr following infection with the attenuated V3032 (Grieder
pend to a significant degree on the pattern of cytokines and Johnston, unpublished observation), indicating the
that are induced following exposure to and/or replication development of a protective mechanism very early in
of a specific virus. Our results show that VEE infection
infection. This absence of an immunoenhancing effect
elicits an immune response characterized by markedly
following IL-12 administration was consistent across the
increased levels of IFN-g and IL-12, cytokines associated
whole range of infectious doses of VEE used; IL-12 had
with a type 1 immune response. However, IL-10, a type
no detectable effect at even the lowest dose of 1 PFU of
2 cytokine, was also increased. Since IL-10 has been
virulent V3000. In contrast to findings involving IL-12, ourshown to inhibit IFN-g elevation (Fiorentino et al., 1991),
results clearly demonstrate that IFN-a/b is an importantit is possible that this cytokine plays a role in the regula-
contributor to protection against VEE, since treatmenttion of the intensity of the immune response to VEE.
with anti-IFN-a/b antibody worsened virulent V3000 in-Recent studies have demonstrated that IL-10 is also as-
fection. We have also recently demonstrated inhibitionsociated with the IFN-g-dominant immune responses fol-
of VEE replication by IFN-a in an activated macrophagelowing certain bacterial infections (Gause et al., 1996;
cell line, supporting the hypothesis that IFN-a plays anSvetic et al., 1993) and that in vivo injections of IL-12
important role in the development of the disease (Griederinduce increased expression of IL-10, as well as IFN-g
and Nguyen, 1996).(Morris et al., 1994). Our studies extend these findings,
Taken together, these results suggest that IL-12 is notdemonstrating that elevated IL-10 is also characteristic of
a major factor in the induction of early protection againstthe type 1 immune response to this acute virus infection.
VEE infection and disease and that other mechanisms,IL-12 has previously been shown to trigger Th1 host
involving IFN-a/b, are present that can rapidly promoteprotective responses to intracellular pathogens. Further,
the development of long-lasting protective immunity.biologically active IL-12 has been shown to have poten-
tial enhancing effects on the immune system (Trinchieri
et al., 1994). This enhancement was demonstrated for
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